Potent Selectivity: Nimbus Entrusts IRAK4 Program To Genentech
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech will take autoimmune disease and cancer compounds into clinical development; Nimbus will get resources for its own clinical studies of NASH candidate.